Dow Sinks 1,450 Points as China Retaliates Against Trump's Tariffs
The Nasdaq slumped 4.7% to 15,781.2, with the S&P 500 down 4.2% to 5,171.9 and the Dow 3.7% lower at 39,043.6 after midday Friday. All sectors slumped intraday, with financials, materials, and technology emerging as the steepest decliners.
"The preliminary estimate of the negative impact of US tariffs from our economists is at least 50 (basis points) on global GDP [gross domestic product] growth and potentially twice as much," UBS said in a note. "We estimate this would imply 250-500kb/d negative impact on oil demand growth, close to half of our 2025 growth forecast of 1.1Mb/d at the upper end."
West Texas Intermediate crude oil futures plunged 9% to
The probability of a 25 basis-point interest-rate cut in May soared to 42% by Friday afternoon, from 22% a day ago, the CME Group's FedWatch Tool showed. All US Treasury yields dropped intraday, with the 10-year yield sliding 14.7 basis points to 3.91% and the two-year rate 20 basis points lower at 3.53%.
Shares of all companies in the Magnificent-7 stable dropped, with Tesla (TSLA) and
"If these tariffs went into place at current form overall tech earnings would come down 15% at least, the supply chain will be a Rubik's Cube rivaling Covid days, and the economy would go into a recession/stagflation,"
MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.
© 1999-2025 Midnight Trader, Inc. All rights reserved.

Related News
-
Coinbase Global Goes From Boom To Bust Amid Crypto Winter, Analyst Trims Q1 Estimates
Benzinga - 51 minutes ago
-
Research Alert: CFRA Cuts Opinion On Shares Of Target Corporation To Hold From Buy
MT Newswires - 11:05 AM ET 4/17/2025
-
These Analysts Slash Their Forecasts On CSX After Weak Earnings
Benzinga - 9:41 AM ET 4/17/2025
-
Top 3 Materials Stocks That Are Ticking Portfolio Bombs
Benzinga - 8:40 AM ET 4/17/2025
-
Datadog, Robinhood And More On CNBC's 'Final Trades'
Benzinga - 8:36 AM ET 4/17/2025
-
Jim Cramer: This Financial Firm Is A Buy, But Not This Semiconductor Stock
Benzinga - 8:31 AM ET 4/17/2025
-
Eli Lilly's Oral GLP-1 Drug Orforglipron Hits Phase 3 Goals In Diabetes Trial, Stock Soars
Benzinga - 7:58 AM ET 4/17/2025